Published in Med J Aust on April 03, 2006
Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care. Health Expect (2013) 0.78
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open (2016) 0.75
Students as teachers. Med J Aust (2013) 2.91
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Confidence of primary care physicians in their ability to carry out basic medical genetic tasks-a European survey in five countries-Part 1. J Community Genet (2010) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
The time course and determinants of blood pressure within the first 48 h after ischemic stroke. Cerebrovasc Dis (2007) 1.39
Effects of gender in amyotrophic lateral sclerosis. Gend Med (2010) 1.38
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Virtual Screening with AutoDock: Theory and Practice. Expert Opin Drug Discov (2010) 1.30
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Motor unit number estimation--a Bayesian approach. Biometrics (2006) 1.25
Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke (2011) 1.23
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Genetics in clinical practice: general practitioners' educational priorities in European countries. Genet Med (2008) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
The effect of ageing on human lymphocyte subsets: comparison of males and females. Immun Ageing (2010) 1.14
Assessing educational priorities in genetics for general practitioners and specialists in five countries: factor structure of the Genetic-Educational Priorities (Gen-EP) scale. Genet Med (2008) 1.14
Immune activation in the peripheral blood of patients with acute ischemic stroke. J Neuroimmunol (2008) 1.14
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Frequency and function of regulatory T cells after ischaemic stroke in humans. J Neuroimmunol (2012) 0.99
Rhizomycosis infection in the basal ganglia. Arch Neurol (2007) 0.98
Allosteric regulation of substrate channeling in tryptophan synthase: modulation of the L-serine reaction in stage I of the beta-reaction by alpha-site ligands. Biochemistry (2007) 0.98
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Educational priorities and current involvement in genetic practice: a survey of midwives in the Netherlands, UK and Sweden. Midwifery (2008) 0.98
INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96
Synthesis and characterization of allosteric probes of substrate channeling in the tryptophan synthase bienzyme complex. Biochemistry (2007) 0.96
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
The SEIQoL-DW is a valid method for measuring individual quality of life in stroke survivors attending a secondary prevention clinic. Qual Life Res (2005) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Impact of premorbid undernutrition on outcome in stroke patients. Stroke (2004) 0.89
Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Genetic education and nongenetic health professionals: educational providers and curricula in Europe. Genet Med (2005) 0.88
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 0.88
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine (2003) 0.86
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86
Optimal stimulation settings for CMAP scan registrations. J Brachial Plex Peripher Nerve Inj (2012) 0.86
Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology (2013) 0.85